[{"id":"76368fa4-a1db-4965-8029-9b8984def53d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01780545","created_at":"2021-01-18T07:50:59.069Z","updated_at":"2024-07-02T16:36:07.518Z","phase":"Phase 2","brief_title":"Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer","source_id_and_acronym":"NCT01780545","lead_sponsor":"Noah Hahn, M.D.","biomarkers":" HSPB1","pipe":" | ","alterations":" HSPB1 expression","tags":["HSPB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HSPB1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • apatorsen (OGX-427)"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 10/01/2017","primary_completion_date":" 10/01/2017","study_txt":" Completion: 10/01/2017","study_completion_date":" 10/01/2017","last_update_posted":"2022-07-11"},{"id":"efdc1e5e-2523-4c6a-a3d5-fe12e37e251d","acronym":"Rainier","url":"https://clinicaltrials.gov/study/NCT01844817","created_at":"2021-01-18T08:13:20.489Z","updated_at":"2024-07-02T16:37:22.179Z","phase":"Phase 2","brief_title":"Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT01844817 - Rainier","lead_sponsor":"SCRI Development Innovations, LLC","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • apatorsen (OGX-427)"],"overall_status":"Completed","enrollment":" Enrollment 132","initiation":"Initiation: 09/01/2013","start_date":" 09/01/2013","primary_txt":" Primary completion: 03/01/2016","primary_completion_date":" 03/01/2016","study_txt":" Completion: 03/01/2016","study_completion_date":" 03/01/2016","last_update_posted":"2017-05-16"},{"id":"89cfcd55-9c32-4558-9659-a541c634f63c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01454089","created_at":"2021-01-18T06:02:15.847Z","updated_at":"2024-07-02T16:37:28.649Z","phase":"Phase 2","brief_title":"A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer","source_id_and_acronym":"NCT01454089","lead_sponsor":"Achieve Life Sciences","biomarkers":" CLU","pipe":"","alterations":" ","tags":["CLU"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • apatorsen (OGX-427)"],"overall_status":"Completed","enrollment":" Enrollment 183","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 11/01/2014","primary_completion_date":" 11/01/2014","study_txt":" Completion: 11/01/2014","study_completion_date":" 11/01/2014","last_update_posted":"2016-10-07"}]